Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

LABT

Lakewood-Amedex Biotherapeutics Inc

May 22 • 04:00PM ET

0.7066

-0.0632 -8.21 %

Healthcare • Biotechnology • USA • Nano • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.88	Insider Own	56.57%	Shs Outstand	7.04M	Perf Week	-52.89%
Market Cap	9.91M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	6.09M	Perf Month	-91.83%
Enterprise Value	11.66M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	1.24%	Perf Quarter	-
Income	-4.23M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.02	Perf Half Y	-
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-834.41%	Short Interest	0.08M	Perf YTD	-91.83%
Book/sh	-0.40	P/C	990.65	EPS next 5Y	-	ROE	-	52W High	9.82 -92.80%	Perf Year	-
Cash/sh	0.00	P/FCF	-	EPS past 3/5Y	17.02% -	ROIC	-	52W Low	0.69 2.41%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	25.26% 25.01%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-53.33%	Oper. Margin	-	ATR (14)	0.82	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.02	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	12.20	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.02	EPS Q/Q	-1900.00%	SMA20	-71.71%	Beta	-	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-76.43%	Rel Volume	0.11	Prev Close	0.77
Employees	5	LT Debt/Eq	-	Earnings	-	SMA200	-76.43%	Avg Volume	4.46M	Price	0.71
IPO	Apr 23, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	552,808	Change	-8.21%

May-18-26 08:02AM	Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers (PR Newswire) -36.65%
May-12-26 08:02AM	Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3 (PR Newswire)
Apr-28-26 07:33AM	Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors (PR Newswire) +6.28%
Apr-23-26 10:42AM	Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT" (PR Newswire)

Lakewood-Amedex Biotherapeutics, Inc. engages in the development of novel antimicrobial therapies. Its anti-infective products targeted certain viral diseases like avian influenza, Epstein Barr Virus (EBV), and hepatitis B and C. The company was founded by Roderic Dale on July 11, 2006 and is headquartered in Bradenton, FL.

CEODr. Kelvin Cooper Ph.D.

CFO & VP of AdministrationMr. Peter F. Ceccacci

Ph.D.Dr. Thomas Balzer M.D.

Project Manager & Accounting ManagerMs. Tara Endress

Investor RelationsDaniel Kontoh-Boateng

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LABT

Lakewood-Amedex Biotherapeutics Inc

Upgrade your Finviz experience